As reported in PR NewsWire; a pivotal Phase II/III trial to create a therapy for activated PI3K delta syndrome (APDS) has announced they’ve successfully completed patient enrollment for a new molecule to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). The community has hopes this could be the first available treatment option for the ultra-rare disease responsible for a range of health conditions.
Activated Phosphoinositide 3-Kinase Delta (PI3Kδ) Syndrome (APDS)
Hopes For The First Treatment Option
We thank patients with APDS and their families, clinical study staff and Novartis for getting leniolisib to this important point in clinical development.”